MaxCyte, Inc.

Jan 11, 2021

Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid's Cell Therapy Programs

Nov 09, 2020

MaxCyte to Present at Two Upcoming Virtual Healthcare Investor Conferences

Oct 13, 2020

MaxCyte Bolsters Leadership Team with Promotion of Brad Calvin to Chief Commercial Officer and New Key VP Appointments

Sep 10, 2020

MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference

Aug 18, 2020

CARMA Cell Therapies(TM) Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11

Jul 08, 2020

APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

Jun 22, 2020

MaxCyte to Present at 2020 European Biotech Investor Day

May 18, 2020

MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting

May 07, 2020

Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement

Apr 06, 2020

MaxCyte to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference

Mar 24, 2020

MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T(TM)) Therapies